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Abstract
The synthesis and exploration of novel butyrophenones have led to the identification of a diazepane
analog of haloperidol, 4-[4-(4-Chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one
(Compound 13) with an interesting multireceptor binding profile. Compound 13 was evaluated for
its binding affinities at DA subtype receptors, 5HT subtype receptors, H-1, M-1 receptors and at
NET, DAT and SERT transporters. At each of these receptors, compound 13 was equipotent or better
than several of the standards currently in use. In in vivo mouse and rat models to evaluate its efficacy
and propensity to elicit catalepsy and hence EPS in humans, compound 13 showed similar efficacy
as clozapine and did not produce catalepsy at five times its ED50 value.
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The introduction of clozapine1 (Clozaril, 1) as a treatment option in the 1990s has opened the
door to the use of atypical antipsychotics and the replacement of the prototypic agent,
haloperidol (2) as a drug of choice for the treatment of schizophrenia. The superior therapeutic
profile of clozapine and other atypical antipsychotic drugs and the long-term debilitating side-
effects2 associated with haloperidol treatment have conspired to diminish its use in the clinic.
Among several hypotheses put forth to explain the long-term extrapyramidal side effects of
haloperidol including tardive dyskinesia, is the fact that haloperidol undergoes
biotransformations that lead to the formation of toxic metabolites.3,4 Specifically, haloperidol
has been shown to undergo CYP450-mediated oxidation to form pyridinium metabolites5
which can potentially damage dopamine receptors in the nigrostriatum of the brain (Chart 1).
Based on this hypothesis, we 6-9 proposed a drug design strategy that replaces the piperidine
ring in haloperidol with bioisosteric equivalents which could not undergo in vivo
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biotransformation to pyridinium species known to be associated with neuronal toxicity. A
similar strategy has more recently appeared in the literature.10 The outcome of such a strategy
was to enhance the pharmacological and side-effect profiles of the resulting agents.
Our laboratory has previously shown that modification in the piperidine ring of haloperidol
results in significant changes in pharmacological activity.6-7 We also identified new
bioisosteric groups of the piperidine ring with binding profiles similar or better than those of
haloperidol at the D2 dopamine receptor subtype.7-9 Several of these compounds are shown
in Chart 2, with new binding affinity data at selected receptors reported in Table 1.
Although compounds 5 and 6 have high affinity for 5HT1A and 5HT2A receptors, the
demonstration that compound 5 elicits a higher catalepsy than haloperidol dampened our desire
to pursue the tropane moiety as a piperidine bioisostere.9 It is important to note that the
alcoholic function in compounds 5 and 6 contributes significantly to affinity not only at the
D2-like receptors but also at the 5HT1A and 5HT2A receptors (cf compounds 5, 6 and 7).
Interestingly, the OH group does not appear to play a significant role in the binding of the
tropane analogs to the 5HT2C receptor.
The reaction mechanism by which haloperidol is metabolized in vivo to a pyridinium species
or BCPP+ has been suggested to begin with dehydration of the tertiary alcoholic function.5 A
drug design strategy to prevent such a biotransformation is to eliminate the alcoholic function.
Compound 3, a haloperidol analog without its alcoholic function, was previously synthesized
and evaluated at D2-like receptors.7 The results supported the notion that the alcoholic function
contributes to affinity but is not an absolute requirement for binding to dopamine receptors.
Compound 4 in which the C-OH group was replaced with a nitrogen atom showed a lower
binding affinity than haloperidol at the dopamine receptors.8 Compounds 5 and 6 were
designed on the premise that the tropane moiety could not form a pyridinium ring due to the
fact that a double bond could not form at the ring junctions adjacent to the N atom.9 In addition,
bridging the ring restricts conformational mobility and holds the alcoholic function in a
preferred conformation.8 Binding evaluation showed that both compounds were as potent or
more potent than haloperidol at D2-like receptors. It was further demonstrated that the OH
group is in the axial position and this led to the suggestion that haloperidol most likely binds
to the dopamine receptors with its OH in the axial position. Comparing 5 and 6 suggests that
the chloro group contributes to binding but is also not an absolute requirement. Removal of
the OH group from the tropane ring (Compound 7) again decreased affinity but retained
sufficient dopamine binding affinity as observed for compound 3. Contraction of the piperidine
ring to a pyrrolidine (8) resulted in a decrease in affinity but expansion to a 7-membered
homopiperidine ring (9) retained affinity as in haloperidol, thus suggesting that homopiperidine
ring is bioisosteric to piperidine ring.7 Separation of the enantiomers of compound 8 and their
subsequent evaluation at D2-like receptors revealed that (+)-8 was the eutomer.6
To further explore these changes in the piperidine moiety of haloperidol in our search for new
antipsychotic drugs with atypical pharmacological profiles, we have embarked on SAR studies
with modifications primarily in the piperidine ring that could lead to the identification of new
agents with clozapine-like binding profiles but without the associated weight gain and new
onset type II diabetes.11 Thus, it was desirable not only to evaluate the binding of the
compounds at dopamine receptors but also at serotonergic receptors (5HT1A and 5HT2A) since
binding to these receptors is often associated with therapeutic advantages observed in atypical
antipsychotic drugs.12 In addition, evaluation of the compounds at 5HT2C and histamine H-1
receptors will be valuable indicators of whether these compounds have the potential to develop
the weight gain side effect associated with atypical antipsychotic drugs.13 In line with the
multiple receptor targeting strategy in the development of new antipsychotic agents, we have
focused our design efforts on obtaining agents that have the following receptor binding profiles:
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a. Binding to DA D2 receptor with moderate affinity (30 < Ki < 150 nM)
b. Binding to DA D4 receptor with high affinity (Ki < 10 nM)
c. Binding to 5HT1A and 5HT2A receptors with high affinity (Ki < 50 nM)
d. Binding to 5HT2C and H-1 receptors with very low affinity (Ki > 500 nM)
The above criteria (a – d) will also guide the selection of compounds for evaluation in in
vivo animal models for efficacy and the propensity of the compounds to produce catalepsy, a
condition associated with extrapyramidal side-effects in humans.14 To achieve the drug design
objectives, we have utilized observations from previous SAR studies to design compounds 10
- 14 (Chart 3) as probes for the dopamine, serotonin and histamine H-1 receptor subtypes in
an attempt to obtain new prototype drugs.
Chemistry
Construction of the ethylene-bridged piperazine moiety was initiated using (2S, 5R)-diethyl
2,5-dibromohexanedioate (16) as the starting material (Scheme 1) as previously reported.15,
16 Double alkylation of 4-chlorophenyl aniline with 16 yielded N-chlorophenyl pyrrolidine
(17). Amidation of 17 with benzylamine produced the amide, 18 which underwent a ring
closure with the remaining ester function to form the bridged piperazine, 19. An attempt to
reduce the lactam functions of 19 with LiAlH4 also resulted in the removal of the 4-chloro
group on the phenyl ring to form the di-substituted 3,8-diaza-bicyclo[3.2.1]octane (20).
Debenzylation of 20 to form 22 was accomplished by reaction with ethyl chloroformate and
the subsequent hydrolytic cleavage of the resulting carbamate, 21. Compound 10 was obtained
by alkylation of the secondary amine function of 22 with 4-chloro-4′-fluorobutyrophenone.
Target compounds 11 and 12 were obtained by alkylating the corresponding starting materials,
23 and 24 respectively (commercially available from Sigma-Aldrich) with 4-chloro-4′-
fluorobutyrophenone (Schemes 2 and 3). Scheme 4 describes the synthesis of target compound
13 in five steps. Initial starting material 4-chloroboronic acid (26) was synthesized from 4-
chlorobromobenzene by lithiation with n-butyl lithium and treatment with trimethylborate. The
chloroboronic acid was coupled to N-Boc protected 1,4-diazepane (28) under palladium-
catalyzed amination condition to form 29. Deprotection of 29 in trifluoroacetic acid delivered
amine 30 which was alkylated in the usual way with 4-chloro-4′-fluorobutyrophenone to form
13. An alternative synthesis of compound 13 was also explored in which the 4-chlorophenyl
homopiperazine (30) was obtained in one step without the protection and deprotection steps.
The reaction involved the coupling of 4-chloroiodobenzene directly with unprotected
homopiperazine under CuI catalysis to form compound 30 in excellent yield. The same
alkylation step delivered the desired compound 13 in 61% overall yield (Scheme 5).
8-Methyl-8-aza-bicyclo[3.2.1]octa-3-one (31) served as the starting material for the synthesis
of target compound 14 (Scheme 5). Compound 31 was converted to the cyclic lactam (32) by
insertion of a nitrogen atom followed by reduction using lithium aluminum hydride to form
33 in very good yield (80%). The free secondary amine in 33 was BOC protected prior to its
treatment with ethyl chloroformate to form the carbamate protected amine, 35. Compound
35 was BOC deprotected and then coupled with 4-chloroboronic acid in the presence of copper
acetate to yield 37. Decarbamylation of 37 was achieved using KOH in ethylene glycol and
the resulting secondary amine was alkylated with 4-chloro-4′-fluorobutyrophenone under the
usual alkylating condition to produce the desired compound 14.
Results and Discussion
Our previous observation that bridging the piperidine ring to form the tropane analogs of
haloperidol resulted in 7- and 3-fold increases in binding affinity at the D2 and D4 receptors
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respectively informed the design of target compounds 10 and 14. The rationale was to
investigate bridged analogs to probe the effect of conformational restriction on piperazine and
homopiperazine equivalents of haloperidol. Compound 10 can also be viewed as an analog of
7 with the carbon at position 4 of the ring replaced by a nitrogen atom. The ethylene bridge in
compound 10 holds the piperazine ring in the chair conformation while in compound 11 the
ring is held in the boat conformation by a methylene group. Binding affinity data for compounds
10 -14 are reported in Table 2.
Both compounds 10 and 11 have only moderate to weak binding affinity at the D2-like receptors
and do not meet the proposed criteria. Interestingly, compound 12, previously reported by
Yevich, J. P. et al.17 with the 4-chlorophenyl ring in compound 4 replaced by 1,3-diazine
moiety, met the four criteria set of interest (Table 3). The authors pharmacologically evaluated
compound 12 and its ketone-reduced analog for their binding affinity for DAD2, sigma and
cortical α1 adrenergic receptors but not at the receptors of interest in this study. Thus, its
synthesis provides an opportunity to compare the contributions of 4-chlorophenyl moiety in
compound 4 with the 1,3-diazine ring in 12 to the binding affinities at the various receptors.
Compound 13, which can be viewed as a homopiperazine analog of haloperidol and compound
9, meets all the criteria except for its binding affinity at the 5HT1A receptor. Compound 14, a
bridged analog of compound 13, also showed low binding affinity for the receptors of interest
(Table 2) and failed to meet the other stated criteria. Thus, it would appear that bridging does
not necessarily result in favorable attributes for these compounds. Based on these observations,
compound 13 was selected for further pharmacological evaluation.
Table 3 shows a head to head comparison of the binding affinities of compound 13 and several
atypical antipsychotic drugs currently in use at several receptors known to have implications
for the therapeutic value of atypical antipsychotic drugs. Compound 13 has moderate affinity
for the DA D2 receptor and high affinity at the D4 receptor. The effect of compound 13 on
apormophine-treated mice (see later) suggests D2 receptor antagonism and thus, would be
expected to demonstrate antipsychotic properties in humans.18 5HT1A receptor activation has
been suggested to contribute to the improved activity of certain atypical antipsychotic drugs.
12b,19
Compound 13 has moderate affinity for 5HT1A (Ki = 117 nM). This binding affinity is higher
than that for risperidone and quetiapine but similar to that of clozapine (Ki = 140 nM).
Compound 13 also binds with high affinity at the 5HT2A receptor (Ki = 23.6 nM), a receptor
implicated in the therapeutic efficacy of atypical antipsychotic drugs in treating the negative
symptoms of schizophrenia and preventing motor disturbances associated with antipsychotic
treatment.20 While this affinity is 10-fold better than that of quetiapine, other atypical
antipsychotics have higher affinity for this receptor. 5HT6 receptors are implicated in the
amelioration of the cognitive disturbances in schizophrenia and both clozapine and olanzapine
have high affinity for this receptor.21 While 13 has weak affinity for the 5HT6 receptor (Ki =
295.8 nM), it is over 13-fold more potent at this receptor than quetiapine and over 6-fold better
than risperidone.
Treatment of schizophrenia with atypical antipsychotic drugs has been associated with weight
gain and the onset of type II diabetes mellitus. Two receptors, histamine H-1 and 5HT2C, have
been suggested to be involved in this adverse event. Several papers22 have demonstrated that
there is significant correlation between affinity for H-1 receptor and weight gain and hence the
observation that compound 13 has much lower affinity (Ki = 186 nM) for H1 receptor than
risperidone (19 nM), quetiapine (8.7 nM), ziprasidone (47 nM), olanzapine (2.8 nM) and
clozapine (1.8 nM) is an indication that compound 13 may have a lower propensity to induce
weight gain. In addition, the low affinity of 13 for the 5HT2C receptor (Ki = 1425 nM) compared
Ablordeppey et al. Page 4













to ziprasidone (Ki = 0.72 nM), risperidone (Ki = 10 nM) and olanzapine (Ki = 10 nM) suggests
a possible decrease in the propensity of 13 for treatment-emergent weight gain. The observation
that 5-HT2B receptor agonists are associated with increased risk for valvular heart disease23
will require that antipsychotics that interact with 5HT receptors be evaluated for binding to the
5HT2B receptor. Thus, it is encouraging to note that compound 13 does not bind appreciably
to 5HT2B receptor (Ki = 495). Also encouraging is the observation that compound 13 lacks
affinity for the cholinergic muscarinic M3 receptor (Ki = 3000 nM), a receptor reported to have
a contributing role in new-onset diabetes in schizophrenic patients treated with atypical
antipsychotics.12a
Compound 13 was also evaluated at neurotransmitter uptake transporters. Compound 13 has
very weak affinity for both the dopamine (DAT) and norepinephrine (NET) transporters but
has similar affinity for the serotonin transporter (SERT) (Ki = 56.6 nM) compared to
aripiprazole (Ki = 98 nM).24 This binding profile at the transporters suggests that while it has
potential for antidepressant properties, it has a much lower potential to induce cocaine-like
adverse properties since it has a very weak binding affinity for DAT.
Animal behavioral studies were initiated to provide preliminary evidence on efficacy and to
evaluate the propensity of compound 13 to induce catalepsy. The ability to block apomorphine
induced stereotypy is an indication of a drug's in vivo capacity to antagonize dopamine D2
receptors while induction of catalepsy is considered to be an indication of a drug's propensity
to produce extrapyramidal symptoms in humans. The ED50 values of compound 13, clozapine
and haloperidol are estimated from the dose-response curves in Figs 1–3. The ED50 value of
compound 13 in inhibiting apomorphine-induced stereotypy was estimated to be 35.8 μmole/
kg compared to clozapine's 42.4 μmole/kg suggesting that compound 13 is slightly more potent
at blocking the D2 receptors in vivo than clozapine on a molar basis. This is also consistent
with their estimated Ki values at the D2 receptor. The ED50 values comparing compound 13,
clozapine and haloperidol is reported in Table 4. Compound 13 and clozapine have ED50s
(μmole/kg) that are about 500 times that of haloperidol. The results of these behavioral studies
support the radioligand binding data that compound 13 does not bind to D2 receptors as well
as haloperidol, but does bind to D2 receptors with about the same affinity as clozapine.
Fig 4 depicts plots of mean catalepsy scores for compound 13 with clozapine and haloperidol
as controls. The vehicle served as a negative control in the study. The ED50 value for each
compound was used as the basis for the dose used for the first set of comparative evaluations.
It is clear that haloperidol showed the highest propensity to induce catalepsy while clozapine
and compound 13 had no significant difference between them. The extent of the absence of
catalepsy was evaluated by increasing the dose of compound 13 up to 5 times the ED50 value
at which point it was impossible to retain the drug in solution for intraperitoneal delivery. At
5× the ED50 value, there was no appreciable cataleptogenic activity observed. Taken together,
the combined receptor binding profile and the absence of catalepsy suggest that compound
13, a butyrophenone analogue which does not induce catalepsy up to 5× its ED50 value may
serve as an atypical antipsychotic agent.
Experimental
Melting points were determined on a Gallenkamp (UK) apparatus and are uncorrected. NMR
spectra were obtained on a Varian 300 MHz Mercury Spectrometer. Elemental analyses were
carried out by Atlantic Microlab, Inc., Norcross, GA and are within 0.4% of theory unless
otherwise noted. Flash chromatography was performed with Davisil grade 634 silica gel. N,N-
Dimethylformamide was distilled from CaSO4 and stored over 4 Ǻ molecular sieves. 4-
Chloro-4′-fluorobutyrophenone was obtained from Sigma-Aldrich but was purified by
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distillation under reduced pressure to a colorless liquid prior to use. Other starting materials
were used without further purification.
Synthesis of compound 10
The synthesis of compound 10 followed the methods previously reported by Cignarella et al.
15 and Thompson et. al.16 as depicted in Scheme 1.
Cis-2,5-dicarboethoxy-1-[4-chlorophenyl]pyrrolidine, 17
To a solution of (2S, 5R)-diethyl 2, 5-dibromo-hexanedioate (16) (10g, 27.8 mmol) in
anhydrous DME (80 mL), was added 4-chloroaniline (14.2g, 111.1 mmol) and KI (1g, 6.02
mmol). The resulting mixture was refluxed under N2 with stirring for 16 h. and allowed to cool
to room temperature. Excess DME was removed under vacuum and the residue was triturated
in Et2O (100 mL) to yield a solid. The solid obtained was filtered, washed with Et2O and the
organic phase was treated with 100 mL of ice cold 5 N HCl and H2O, dried over MgSO4 and
solvent removed in vacuo. The crude compound was purified by chromatography on silica gel




A mixture of cis- and trans-2,5-dicarboethoxy-1-[4-chlorophenyl]pyrolidine, 17 (8.5g, 26
mmol) was dissolved in 10 mL of o-xylene. Benzylamine (3.61 g, 33.74 mmol) was added to
the reaction mixture and refluxed for 18 h. under N2, cooled and solvent evaporated. The
residue was subjected to column chromatography (silica gel) eluting with (1:1) hexane: EtOAc
to give compound 18 (4.4 g, 39.8 %). 1H NMR (300 MHz, CDCl3) δ 1.19 (t, J = 7.13 Hz, 3H),
2.01-2.45 (m, 4H), 4.11-4.37 (m, 4H), 4.40-4.46 (dd, J = 6.0, 3.2 Hz, 2H), 6.36-6.44 (m, 2H),
7.09-7.24 (m, 7H), 8.52 (m, 1H).
3-Benzyl-8-[4-chlorophenyl]-3,8-diazabicyclo[3.2.1]octane-2,4-dione, 19
The solution of compound 18 (4.0 g, 10.35mmol) in 30 mL of 1N NaOH (75% aq. ethanol)
was stirred at room temperature for 2 h. The reaction was quenched with HCl gas to the end
point of phenolphthalein and the solid was filtered. The solvent was removed in vacuo and the
solid material was re-dissolved in absolute alcohol. The solution was partially removed in
vacuo and the residue was treated with Ac2O (5 mL) and NaOAc (1 g). After refluxing
overnight under N2, the excess Ac2O was removed and the reaction mixture was quenched
with aq. Na2CO3, extracted with CH2Cl2 (3 × 100 mL) and dried over anhydrous MgSO4. The
solvent was removed in vacuo and separated on a silica gel column (7:3 hexane : EtOAc) to
give compound 19 (2.56 g, 56.7%, white solid, mp 163-164 °C). 1H NMR (270 MHz,
CDCl3) δ 2.04-2.12 (m, 2H), 2.46-2.55 (m, 2H), 4.63-4.66 (dd, J = 5.1, 2.7 Hz, 2H), 4.70 (s,
2H), 6.70-6.82 (m, 4H), 7.03-7.12 (m, 5H).
3-Benzyl-8-phenyl-3, 8-diazabicyclo[3.2.1]octane, 20
To a solution of compound 19 (0.58 g, 1.70 mmol) in anhydrous THF (3 mL), was added
slowly, 1 M LiAlH4 (10.24 mL, 10.24 mmol) and refluxed for 2 days under N2. The reaction
was quenched in ice bath with 10% NaOH (20 mL) and extracted with CH2Cl2. The organic
phase was separated, dried over MgSO4 and removed in vacuo. The residue was subjected to
column chromatography (silica gel, 9:1 hexane:ethyl acetate) to give compound 20 (0.4 g,
84.6%, white crystals, mp 115-117 °C). 1H NMR (270 MHz, CDCl3) δ 1.87-2.08 (m, 4H),
2.51-2.52 (d, J = 2.0 Hz, 4H), 3.41 (s, 2H), 4.13-4.15 (m, 2H), 6.65-6.78 (m, 3H), 7.15-7.30
(m, 7H).
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To a solution of compound 20 (0.77 g, 2.8 mmol) in anhydrous toluene (15 mL), was added
ethyl chloroformate (1.6 mL, 16.6 mmol) and refluxed for 16 h under N2. The resulting solution
was allowed to cool to RT and excess solvent was removed under vacuum. The resulting residue
was subjected to column chromatography (silica gel, 8:2 hexane:ethyl acetate) to give
compound 21 (0.65 g; 90.5%) as white crystals, mp 124.4 °C. 1H NMR (270 MHz, CDCl3) δ
1.22 (t, J = 8.1 Hz, 3H), 1.79-1.84 (m, 2H), 1.98-2.04 (m, 2H), 3.29 (t, J = 13.5 Hz, 2H),
3.60-3.76 (dd, J = 13.5 Hz, 2H), 4.07-4.18 (m, 4H), 6.70-6.80 (m, 3H), 7.18-7.26 (m, 2H).
8-Phenyl-3,8-diazabicyclo[3.2.1]octane, 22
To a solution of compound 21 (0.73 g, 2.48 mmol) in EtOH (5 mL), was added KOH [3 g in
H2O (3 mL)], EtOH (25 mL) followed by NH2NH2 (3 mL). The resulting mixture was refluxed
for 16 h. Excess alcohol was removed and the residue was extracted with EtOAc (4 × 50 mL)
and H2O (20 mL) to give compound 22 (0.4 g 86%). 1H NMR (270 MHz, CDCl3) δ 1.88-2.07
(m, 4H), 2.51-2.57 (dd, J = 13.5, 2.7 Hz, 2H), 3.19-3.24 (d, J = 13.5 Hz, 2H), 4.09 (br s, 2H),
6.67-6.78 (m, 3H), 7.17-7.24 (m, 2H).
8-Phenyl-3,8-diazabicyclo[3.2.1]octan-1-yl-1-(4-fluorophenyl)butan-1-one, 10
To a mixture of compound 22 (0.56 g, 2.96 mmol), K2CO3 (1.4g, 10 mmol) and KI (0.3 g) in
DME (10 mL), was added 4-chloro-4-fluorobutyrophenone (2.0 g, 10.01 mmol) and stirred.
The mixture was refluxed for 16 h under N2 atmosphere and the reaction mixture was allowed
to cool to room temperature. Excess DME was removed in vacuo and the residue was extracted
with CH2Cl2 (3 × 50 mL) followed by brine (50 mL). The organic phase was collected and
dried over anhydrous MgSO4 and the solvent evaporated. The resulting crude product was
subjected to column chromatography (silica gel, 8:2 EtOAc:MeOH) to give an oily residue
(1.21 g, 68.2 %) and subsequently converted to an oxalate salt as a white solid, mp 194.7-195.5
°C. 1H-NMR (270 MHz, CDCl3) δ 1.89-1.99 (m, 6H), 2.39 (t, J = 6.8, 2H), 2.47-2.65 (m, 4H),
3.06 (t, J = 7.3, 2H), 4.21 (m, 2H), 6.73-6.85 (m, 3H), 7.17-7.33 (m, 4H), 8.05-8.10 (m, 2H).
Anal. (C24 H26CFN2O5:H2O) calcd. C 64.62, H 6.19, N 6.28. Found C 64.66, H 6.11, N 6.14.
4-[5-(4-Chloro-phenyl)-2,5-diaza-bicyclo[2.2.1]hept-2-yl]-1-(4-fluoro-phenyl)-butan-1-one, 11
A mixture of compound 23 (0.5g, 2.4 mmol), 4-chloro-4-fluorobutyrophenone (1.9g, 9.6
mmol) KI (50mg) and K2CO3 (138 mg) in DME (10 ml) was refluxed in an atmosphere of
N2 for 60 hours. Excess DME was removed under vacuum and residue was partitioned between
CH2Cl2 (3 × 75 ml) and brine (50 ml). The organic phase was pooled, dried over anhydrous
Na2SO4 and the solvent removed in vacuo to afford a residue as the crude product. The crude
product was purified by column chromatography using 0 - 20% MeOH in EtOAc to yield
compound 11 (755mg, 84.5%), which was subsequently converted to the oxalic acid salt as a
white crystal, mp 116.4 -116.8 °C. 1H-NMR (300 MHz, DMSOd6) δ 1.86-1.93 (m, 4H),
2.09-2.21 (AB system, J=10.7, 2H), 3.00-3.37 (m, 6H), 3.11 (t, J=6.7, 2H), 3,37-3.58 (AB
system, J=9.3, 2H). 4.42 (m, 1H), 4.60 (m, 1H), 6.65-6.68 (Part of AAXX, 2H), 7.32-7.38 (Part
of AAXX, 2H), 8.00-8.04 (Part of AAXX, 2H). Anal. C21H22ClFN2O.1.5C2H2O4 calcd: C
56.73, H 4.96, N 5.52; Found: C 56.49, H 4.91, N 5.42
4-[4-(2-Pyrimidine)piperazin-1-yl]-1-(4-fluorophenyl)butan-1-one, 12
A mixture of 2-(piperazin-1-yl)pyrimidine dihydrochloride (0.5g, 2.1 mmol), 4-chloro-4′-
fluorobutyrophenone (1.3 g, 6.3 mmol), KI (25 mg), K2CO3 (1.5 g, 10.9 mmol), in DME (10
mL) was refluxed with stirring under N2 for 12 h. After cooling to room temperature, the
mixture was diluted with EtOAc (200 mL) and washed with H2O. The organic layer was dried
(Na2SO4) and filtered. The filtrate was concentrated in vacuo to dryness and the residue was
purified by chromatography on silica gel to give compound 12 (563 mg, 78%), mp 109 -110
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°C. 1H NMR (CDCl3): 8.29 (2H, d, J = 4.5 Hz), 8.02 (2H, dd, J = 5.1, 8.7 Hz), 7.13 (2H, t, J
= 8.7 Hz), 6.47 (1H, t, J = 4.5 Hz), 3.76 (4H, m), 3.01 (2H, t, J = 7.5 Hz), 2.46 (6H, m), 1.99
(2H, m). Calcd for C18H21FN4O: C, 65.84; H, 6.45; N, 17.06. Found: C, 65.91; H, 6.51; N
16.86.
4-Chlorophenylboronic Acid, 26
To a solution of 4-bromochlorobenzene, 25 (4 g, 20.9 mmol) in THF (80 mL) was added n-
BuLi (22 mL, 1.6 M) at −78 °C under N2 and stirred for 1h at the same temperature. The
reaction mixture was treated with B(OMe)3 (398.8 ml, 78.3 mmol) at −78 °C, allowed to warm
up to room temperature and then stirred overnight. The pH of the mixture was then adjusted
with a solution of NaHCO3 to pH 6.5 and extracted with CH2Cl2 (3 × 150 mL). The pooled
organic phase was dried (MgSO4), the solvent was removed in vacuo and the crude product
was column chromatographed (silica gel, 7:3, hexane:EtOAc) to yield compound 26 (4-
chlorophenyl-boronic acid) (2 g, 61 %) as a white solid. 1H-NMR (270 MHz, CD3OD) δ
7.30-7.77 (m, 4H).
1-t-Butyl homopiperazine carboxylate, 28
To a solution of homopiperazine, 27 (10g, 0.1 mol) in H2O (104 mL) and t-BuOH (119 mL)
containing 2.5 N NaOH (16 mL) was added di-tert-butyl dicarbonate (8.55 g, 0.039 mol) at 0
°C for 40 min. The resulting mixture was stirred for 1 h at room temperature and the solution
was concentrated in vacuo. The crude material was extracted with CH2Cl2 (3 × 100 mL), dried
over MgSO4 and the solvent evaporated. The crude product was subjected to column
chromatography (silica gel, 9:1:1 MeOH : CH2Cl2 : NH4OH to give 1-t-Butyl homopiperazine
carboxylate, 28 (5 g, 64 %). 1H-NMR (270 MHz, CD3OD) δ 1.46 (s, 9H), 1.79 (q, J=5.9, 2H),
2.78-2.87 (m, 4H), 3.41-3.49 (m, 4H).
1-t-Butyl-4-(4-chlorophenyl)homopiperazine carboxylate, 29
The mixture of 4-chlorophenyl-boronic Acid, 26 (1.65 g, 10.54 mmol), 28 (1.05g, 5.27 mmol),
Cu(OAc)2 (1.43 g, 7.87 mmol), triethylamine (0.726 mL) and molecular sieves (4 g) in
CH2Cl2 (50 mL) was stirred at room temperature under air. The reaction was quenched with
a 4 ml of NH4OH in 4 mL of MeOH. The mixture was filtered through celite and purified by
column chromatography using hexane:EtOAc (7:3) as eluent on silica gel to give compound
29 (1.2 g, 73%) 1H-NMR (300 MHz, CDCl3) δ 1.35 (s, 4H), 1.42 (s, 5H), 1.91-1.98 (m, 2H),
3.18 (t, 1H, J = 6.2 Hz), 3.29 (t, 1H, J = 6), 3.48-3.7 (m, 6H), 6.58 (d, 2H, J = 8.7 Hz), 7.12
(m, 2H, J = 9 Hz)
1-(4-Chlorophenyl)homopiperazine, 30
Trifluoroacetic acid (5 mL) was slowly added in a drop-wise manner to a solution of compound
29 in CH2Cl2 (5 mL) at ambient temperature and the resulting mixture was allowed to stir
overnight. The reaction was quenched with aq. NaOH and extracted with EtOAc (3 × 100 mL),
washed with NaHCO3 solution (50 mL) and brine (50 mL). The organic phase was collected
and dried over MgSO4 and evaporated in vacuo. The crude product was subjected to column
chromatography (silica gel, 9:1:1 MeOH: CH2Cl2 :NH4OH to yield 1-(4-chlorophenyl)
homopiperazine, 30 (0.720 g, 88%). 1H-NMR (300 MHz, CDCl3) δ 1.92-1.98 (m, 2H), 2.86
(t, 2H, J = 5.7), 3.04 (t, J = 5.4 Hz), 3.53 (q, 4H, J = 6.4 Hz), 5.50 (br s, 1H), 6.58 (d, 2H, J =
9), 7.14 (d, 2H, J = 9.2 Hz).
4-[4-(4-Chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one, 13
A mixture of compound 30 (709 mg, 3.4 mmol) in dry DME (15 mL) and K2CO3 (1.9 g, 13.9
mmol) was heated for 20 min. after which 4-chloro-4-flourobutyrophenone (2.8 g, 13.9 mmol)
was added followed by KI (0.3 g). The reaction mixture was refluxed for 18 h under an
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atmosphere of N2. Excess DME was removed in vacuo and the residue was extracted with
CH2Cl2 (3 × 100 mL) and brine (50 mL). The organic phase was collected and dried over
MgSO4 and solvent removed under vacuum. The crude product was subjected to column
chromatography (silica gel, 9:1 EtOAc:MeOH) to yield compound 13 (1.19 g, 87%) as an
oil. 1H-NMR (300 MHz, CDCl3) δ 1.84-1.95 (m, 4H), 2.53-2.62 (m, 4H), 2.75 (t, 2H, J = 5.1
Hz), 2.93 (t, 2H, J = 7.2 Hz) 3.39-3.48 (m, 4H), 6.58 (d, 2H, J = 9.6 Hz), 7.05-7.13 (m, 4H),
7.96-7.92 (dd, 2H, J = 9, 5.1 Hz). Subsequently, compound 13 was converted to the oxalate
salt, crystallized from MeOH/Et2O as a white solid, mp 146.6-146.4 °C. Anal.
(C23H26ClFN2O2) calcd. C 59.42, H 5.64, N 6.03 found C 59.27, H 5.70, N 6.05.
Alternative Method for Compound 13
A mixture of homopiperazine (2 g, 20 mmol), CuI (380 mg, 2 mmol), K2CO3 (5.5 g, 40 mmol),
ethylene glycol (2.4 g, 40 mmol), 1-chloro-4-iodobenzene (4.76 g, 20 mmol) in iPrOH (50 mL)
was refluxed for 12 h under N2. The mixture was diluted with EtOAc (500 mL) and washed
with water. The organic phase was dried (Na2SO4), and filtered. The filtrate was concentrated
in vacuo to dryness followed by chromatography on silica gel (EtOAc then MeOH/EtOAc
=10/90) to afford 1-(4-chlorophenyl)-1,4-diazepane (3.8 g, 90%).
A mixture of 1-(4-chlorophenyl)-1,4-diazepane (30) (540 mg, 2.57 mmol), 4-chloro-4-
fluorobutyrophenone (2 g, 10.28 mmol), KI (25 mg), K2CO3 (880 mg, 6.38 mmol) in DME
(20 mL) was refluxed under N2 for 12 h. The mixture was diluted with EtOAc (500 mL) and
washed with H2O. The organic phase was dried (Na2SO4), and filtered. The filtrate was
concentrated in vacuo to dryness followed by column chromatography on silica gel (pure
EtOAc) to afford 4-[4-(4-chlorophenyl)-1, 4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one,
13. The product was converted to the salt form using ethereal HCl and then crystallized from
MeOH/Et2O to give the pure HCl salt (715 mg, 68%) mp 165-166 °C, 1H NMR (DMSO): δ
10.48 (1H, brs), 8.04 (2H, dd, J = 5.7, 9.3 Hz), 7.35 (2H, t, J = 8.7 Hz), 7.19 (2H, d, J = 9.3
Hz), 7.76 (2H, d, J = 9.3 Hz), 3.78 (2H, m), 3.42 (4H, m), 3.15 (6H, m), 2.38 (1H, m), 2.15
(1H, m), 2.03 (2H, m). Calcd for C21H25Cl2FN2O: C, 61.32; H, 6.13; N, 6.81. Found: C, 61.20;
H, 5.98; N, 6.78.
9-Methyl-3,9-diazabicyclo[4.2.1]nonan-4-one, 32
Using the method reported by Michaels and Zaugg,25 conc. H2SO4 (37.5 mL) was added drop
wise at −20 °C, to a mixture of tropinone, 31 (16.7g, 32 mmol) in anhydrous CHCl3 (120 mL).
This was followed by a slow addition of sodium azide (15.6 g) for 30 minutes while maintaining
the temperature below −5 °C. After completing the addition, the reaction mixture was stirred
at room temperature for 15 min, and then heated at 50 °C overnight under nitrogen. The reaction
mixture was then neutralized with NaHCO3, extracted with CH2Cl2, and the organic layer was
collected, dried over Na2SO4 and evaporated in vacuo to afford a light yellowish substance as
32 (13.8 g, 78 %); MS: 155 (M+1)+, IR (KBr): 3190 (-NH), 1620 (C=O).
3,9-Diazabicyclo[4.2.1]nonane-3,9-dicarboxylic acid 3-tert-butyl ester 9-ethyl ester, 35
To a solution of compound 32 (15.2g, 30 mmol) in anhydrous THF (100 mL), was added very
slowly under nitrogen powdered LAH (14.1 g, 8 eq). The mixture was allowed to stir at room
temperature overnight before being quenched with MeOH, followed by H2O, filtered, washed
twice with CH2Cl2, extracted, dried over Na2SO4 and evaporated to yield 9-Methyl-3,9-
diazabicyclo[4.2.1]nonane, compound 33 (11 g, 80 %). TLC analysis showed a single spot and
was used as such without characterization. Compound 33 (12.0 g, 24 mmol) was dissolved in
15 mL of t-BuOH and added a solution of Boc-anhydride (5.8g, 28mmol) in t-BuOH (10 mL)
for 5 min. and the reaction mixture was stirred overnight. The reaction was then neutralized
with NaHCO3, extracted with CH2Cl2, dried over Na2SO4 and evaporated in vacuo to yield 9-
Methyl-3,9-diazabicyclo[4.2.1]nonane-3-carboxylic acid t-butyl ester, 34 (13.8 g, 67 %).
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Compound 34 (5.8 g, 32 mmol) was dissolved in anhydrous toluene (20 mL) and ethyl
chloroformate (3.6 g, 33.3 mmol) was slowly added in a drop-wise manner. The reaction
mixture was refluxed overnight and the solvent was evaporated as an azeotrope with alcohol.
The resulting product, 3,9-diazabicyclo[4.2.1]nonane-3,9-dicarboxylic acid 3-tert-butyl ester
9-ethyl ester, 35 was dried and used as such without further purification for the next reaction.
3-(4-Chlorophenyl)-3,9-diazabicyclo[4.2.1]nonane-9-dicarboxylic acid ethyl ester, 37
Compound 35 (5.5 g, 18.4 mmol) was dissolved in CF3COOH (3 mL) and stirred for 4h at
room temperature. The reaction mixture was then neutralized with NaHCO3, extracted with
CH2Cl2, dried over Na2SO4 and evaporated to get a light yellowish oil, 3,9-diazabicyclo[4.2.1]
nonane-9-carboxylic acid ethyl ester, 36 (2.85 g, 78 %). Compound 36 (5 g, 25.6 mmol), 4-
chlorophenylboronic acid (5.6 g, 35.8 mmol), Cu(OAc)2 (5.7g, 31.4 mmol) and Et3N (2 mL)
in CH2Cl2 (50 mL) with molecular sieves (2 g) was stirred in open air for 48 h. The reaction
mixture was then quenched with methanolic NH3 solution, filtered over celite, extracted with
CH2Cl2 (100 mL), dried and solvent evaporated under vacuum. The crude residue was
subjected to column chromatography (silica gel, 4:1 CH2Cl2:MeOH) to give a yellowish
compound 37 (4.5 g, 58 %). 1H NMR (300MHz, CDCl3): δ 1.20-1.26 (m, 3H), 1.39-1.6 (m,
2H), 1.75-1.95 (m, 2H), 2.0-2.29 (m, 2H), 3.0-3.30 (m, 2H), 3.54-3.68 (m, 1H), 3.70-3.8 (m,
1H), 4.05-4.20 (m, 2H), 426-4.43 (m, 2H), 6.62-6.66 (dd, 2H, J = 7.8, 3.3 Hz), 7.06-7.12 (m,
2H).
3-(4-Chlorophenyl)-3,9-diazabicyclo[4.2.1]nonane, 38
Compound 37 (2.2 g, 7.12 mmol), 50 % aq. KOH (2 ml) in ethylene glycol (2 mL) was heated
at 90 °C overnight. The reaction mixture was then extracted with CH2Cl2 (2 × 80 mL), dried
over Na2SO4 and evaporated under vacuum. The crude product was subjected to column
chromatography (silica gel, 4:2 CH2Cl2:MeOH) to yield compound 38 (0.99 g, 59 %). 1H NMR
(300MHz, CDCl3): δ 1.32-1.76 (m, 4H), 1.90-2.25 (m, 4H), 3.15-3.35 (m, 4H), 6.63 (d, 2H,
J = 9 Hz), 7.09 (d, 2H, J = 9 Hz).
4-[3-(4-Chlorophenyl)-3,9-diazabicyclo[4.2.1]non-9-yl]-1-(4-fluorophenyl)butan-1-one, 14
A mixture of compound 38 (0.45g, 1.9 mmol) and K2CO3 (1g, 7.6 mmol) in dry DME (15 mL)
was heated at 80 °C for 20 minutes and 4-chloro-4-fluorobutyrophenone (2.2 ml, 7.6 mmol)
was added in a drop-wise manner and refluxed overnight under nitrogen. Excess DME was
removed in vacuo and the residue was extracted with CH2Cl2 (3 × 60 ml). The pooled organic
phase was collected and dried over Na2SO4 and evaporated under vacuum. The crude product
was subjected to column chromatography (silica gel, 4:1 CH2Cl2-EtOAc) to yield compound
4 (0.55 g, 68.2 %) as an oil which was converted into the oxalate salt. (White crystalline solid,
mp:182-184 °C). 1H NMR (300 MHz, CDCl3): δ 1.20 -1.66 (m, 4H), 1.80-2.00 (m, 4H),
2.50-2.75 (m, 2H), 2.90-3.05 (m, 2H), 3.35-3.60 (m, 6H), 6.58 (m, 2H), 7.05-7.15 (m, 4H),
7.91-7.97 (m, 2H), Anal. Calcd. for C25H26N2O5ClF: 0.25H2O: C, 60.61; H, 5.80; N, 5.65.
Found C, 60.53; H, 5.75, N, 5.53.
Biology
Receptor Binding Studies
Binding affinities reported in Tables 1 – 3 were conducted by the National Institute of Mental
Health Psychoactive Drug Screening Program (NIMH-PDSP) unless otherwise stated. Details
of the methods and radioligands used for the binding assays were previously reported.26
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Apomorphine Induced Climbing Stereotypy
A modified climbing test by Needham et al. was used27 and provides the extent a potential
antipsychotic agent inhibits the effect of apomorphine induced stereotypy. Swiss Webster male
mice (∼30 g) in groups of 5 were administered an intraperitoneal (IP) injection of 0.3 mL of
vehicle (filtered 1% lactic acid) or increasing doses of the dopamine antagonists haloperidol
(0.001, 0.01, 0.02, 0.05, 0.1, 0.2 mg/kg), compound 13 (12, 15, 17, 20, 25, 50, 80 mg/kg), and
clozapine (3, 10, 20, 30, 60 mg/kg). Animals were then challenged at 30 minutes post injection
with 1.5- 1.6 mg/kg of the agonist apomorphine in 0.9% NaCl + 0.1% ascorbic acid, placed in
cylindrical wire cages (12 cm in diameter, 14 cm in height), and observed for climbing behavior
at 10 and 20 minutes post dose. Climbing behavior was assessed as follows: 3-4 paws on the
cage floor = 0 score; 2 and 3 paws on the cage = 1 score; 4 paws on the cage = 2 score. Scores
were expressed as mean % climbing inhibition, and plotted in figures 1-3. ED50s in Table 4
were calculated using Graph Pad Prism non-linear regression software with sigmoidal dose-
response, variable slope curve-fitting.
Bar Test for Catalepsy
The bar test used by Hoffman and Donovan28 was modified for our use. Male Sprague-Dawley
rats (88-207 g) in groups of 5-8 were dosed by IP injection with 1-23 mL/kg of vehicle (filtered
1% lactic acid), haloperidol (0.3 mg/kg), compound 13 (28, 42, 70 mg/kg), or clozapine (30
mg/kg). Catalepsy severity was assessed at time points (15, 30, 45, 60, and 90 min) post
injection, by scoring how long the rat maintained both forepaws motionless on a horizontal
metal bar (1.1 cm in diameter, 10 cm above the bench top in a box) up to a maximum of 120
seconds. This was repeated 2 more times and the average (n=3 tries) seconds recorded for each
rat. The mean of all the average seconds for one dose for one time point (n=5-8 rats) was divided
by 5 and a mean catalepsy score assigned and plotted in figure 4 with a maximum possible
score of 24.
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a Reagents: (i) 4-Chloroaniline, DME, KI; (ii) Benzylamine, o-Xylene; (iii) (a) NaOH, EtOH;
(b) Ac2O, NaOAc; (iv) LiAlH4; (v) ClCO2Et, Toluene; (vi) KOH, EtOH, NH2NH2; (vii) 4-
Chloro-4′-fluorobutyrophenone, KI, K2CO3, DME.
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a Reagents: (i) 4-Chloro-4′-fluorobutyrophenone, KI, K2CO3, DME.
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a Reagents: (i) 4-Chloro-4′-fluorobutyrophenone, KI, K2CO3, DME.
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a Reagents: (i) (a) n-BuLi, -78 °C, THF; (b) B(OMe)3; (ii) t-BuOH, NaOH, (t-BuOCO)2O; (iii)
Cu(OAc)2, NEt3, Mol sieves (4Å), rt; (iv) TFA, CH2Cl2; (v) 4-Chloro-4′-fluorobutyrophenone,
KI, K2CO3, DME.
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Alternative Synthetic Scheme for Compound 13
a Reagents and conditions: (i) CuI, ethylene glycol, K2CO3, iPrOH, 80 °C, reflux, 12 h; (ii):
KI, K2CO3, DME, 4-chloro-4′-fluorobutyrophenone, reflux, 12 h.
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a Reagents: (i) H2SO4, NaN3; (ii) LiAlH4, THF; (iii) t-BuOH, (t-BuOCO)2O; (iv) ClCO2Et,
Toluene; (v) TFA (vi) 4-Chlorophenylboronic Acid, Cu(OAc)2, Et3N, CH2Cl2, Mol sieves
(4Å), RT, 24 – 48 hr; (vii) KOH, Ethylene glycol; (viii) 4-Chloro-4′-fluorobutyrophenone, KI,
K2CO3, DME.
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Table 4
Comparison of ED50 values for Apomorphine Test
Test Compound FW ED50, mg/kg 95% Confidence Interval, mg/kg ED50, μmoles/kg
Compound 13 411.3 14.7 13.4 to 16.1 35.8
Clozapine 326.8 13.8 7.57 to 25.3 42.4
Haloperidol 375.9 0.0293 0.0112 to 0.0768 0.0779
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